Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
about
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsExperience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesBiosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.CT-P13: design, development, and place in therapyEffects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.The Role of Biosimilars in Inflammatory Bowel Disease.Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.CT-P13 in the treatment of rheumatoid arthritis.Insights on the use of biosimilars in the treatment of inflammatory bowel disease.Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future.Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.Maintenance therapy options for ulcerative colitis.Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.Biosimilars in inflammatory bowel disease: A review of post-marketing experience.Emerging biologics in inflammatory bowel disease.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassaysEuropean Experience of Infliximab Biosimilars for the Treatment of Inflammatory Bowel Disease.Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars.Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.Comparative effectiveness of the biosimilar CT-P13.Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis.
P2860
Q26748630-F89C6C58-2D08-433C-A1EF-F17A81D1592AQ28066776-6A24A3A6-0E3B-428F-80AD-5324A969CC7EQ30393052-FC82F8CB-654B-469D-942F-7974FF0F7C67Q30397234-E1E71224-3705-4C4D-8AA5-7E1D99F89E23Q33803728-94C486A1-C020-43C2-A4A0-88618270FC46Q36347059-9F623A48-4D69-4F8B-9D69-3E980AEB8C2CQ37051515-634F2AD4-A86F-427B-B602-BFA4A4570D11Q37540190-C83E4699-0458-4E77-8E2D-D0E41A023CF6Q38609741-1820382B-0E30-4BB6-A3D3-AE7E9C9B9528Q38633561-082D16CB-D694-4566-B1BD-A0B9A49B45D3Q38676104-200E2AB4-7967-45CE-AB5D-658439D789FCQ38735477-EF41E60B-6869-4442-8973-AF762EA0D0DDQ38786144-80BE1F63-F680-48F5-A05D-45F4E2789A4DQ38816194-3F3C007B-C289-4663-8DE7-0A9B60D41A24Q38824505-0CF14E9F-7957-4140-9B2B-2318E94B00CCQ38826838-A11569B2-E52E-424E-B9A2-7F13090763AEQ38848140-2D27AFAD-3A72-48C5-ACFF-5DECDDF890FEQ38850063-94722DC1-5F82-4845-B484-BDA828AD93D7Q38937842-949AE7BD-83AA-4892-A99B-DF4D6DBEEFF4Q38960108-1AD39C7C-C377-442A-97DD-2989F4C0EEF6Q38977625-59B362D1-623F-432B-85BC-26F839200249Q38994573-16F04138-A045-4A45-A29A-5DD7F55B8CAFQ38996437-E9499D0F-34E7-4F9B-80A3-4C82ECA209A7Q39004625-C4F58442-9321-4F4F-B53D-C4E6A6D8FCC9Q39016810-12CEAA6A-53A4-447A-A822-D3DC68C53F2EQ39018436-C448701E-3F2E-4740-8870-C3015353C20EQ39051341-AA327EF7-1B48-4318-8588-CA651C2EDE33Q39152159-78EB4C8E-FEE4-41F2-9259-8D78D1CD7362Q39192318-A3DC68B0-3999-4775-8B07-E02FC65BE4E2Q39359495-4EE6B21E-B706-4688-82D4-B68B3D16152FQ41078498-F5AFE43F-5127-454B-AFD9-5D01FC525D3CQ41504139-656DCBEA-6807-4DF4-866A-F56E1A3B6DA0Q42332419-E8B66E91-D226-4809-A5D1-F6C280078F6BQ42701889-7E6E8C1A-B257-4BD4-B6C5-4720D74D2F7BQ47418286-C9D2D8AA-818B-4CDD-82E7-F02A2217BDA8Q47662817-636D0EFC-AD0A-4D4B-B759-5B8A7C423353Q47785572-EE97E26F-3F91-45D4-995F-7BE5D55C63DBQ48059378-59716F55-5BFD-435D-8A11-567829AD63BCQ48217871-BC60B4F0-4C37-4949-9299-A4856FD745BFQ49596689-E4A81901-AD27-423E-B207-A5908A587556
P2860
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy and Safety of the Bio ...... ulticentre, Nationwide Cohort.
@en
type
label
Efficacy and Safety of the Bio ...... ulticentre, Nationwide Cohort.
@en
prefLabel
Efficacy and Safety of the Bio ...... ulticentre, Nationwide Cohort.
@en
P2093
P356
P1476
Efficacy and Safety of the Bio ...... ulticentre, Nationwide Cohort.
@en
P2093
Balázs Szalay
Barbara D Lovász
Beáta Gasztonyi
Ferenc Nagy
Gábor T Tóth
János Banai
Klaudia Farkas
Krisztina B Gecse
Károly Palatka
Lilla Lakner
P304
P356
10.1093/ECCO-JCC/JJV220
P577
2015-12-10T00:00:00Z